drugset / Trial / NCT02704494
Resveratrol's Effects in Diabetic Nephropathy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this study is to evaluate the safety and effects of resveratrol in treatment of diabetic nephropathy.
Timeline
- Start
- 2016-03
- Primary completion
- 2017-02
- Completion
- 2017-02
Outcome
Mixed primary results
paper Primary outcomes were urinary albumin/creatinine ratio, estimated glomerular filtration rate (eGFR) and serum creatinine levels. PMID 29983230 ↗
paper After adjusting for confounding variables, the effect of resveratrol in reducing urinary albumin excretion was still significant (P<0.001). PMID 29983230 ↗
paper eGFR (1.7mL/min/1.73m2, 95% CI: -3.4 to 6.8 vs -4.0, 95% CI: -8.2 to 0.2; P=0.08) PMID 29983230 ↗
paper serum creatinine (-0.3mg/dL, 95% CI: -0.1 to 0.1 vs 0.1mg/dL, 95% CI: -0.0 to 0.1; P=0.13) were unchanged. PMID 29983230 ↗
Publications
- Colombijn JM, Hooft L, Jun M, Webster AC, Bots ML, Verhaar MC, Vernooij RW. Antioxidants for adults with chronic kidney disease. Cochrane Database Syst Rev. 2023 Nov 2;11(11):CD008176. doi: 10.1002/14651858.CD008176.pub3.
- Sattarinezhad A, Roozbeh J, Shirazi Yeganeh B, Omrani GR, Shams M. Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial. Diabetes Metab. 2019 Jan;45(1):53-59. doi: 10.1016/j.diabet.2018.05.010. Epub 2018 Jun 8.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resveratrol | Small molecule | 500 mg | — |
| Background | Losartan | Other / unclassified | 12.5 mg | — |